Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phio Pharmaceuticals Corp. (NASDAQ: PHIO) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phio is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology in immuno-oncology, with a lead program, PH-762, targeting the PD-1 gene in skin cancers.
Through this page, you can review current and historical Forms 8-K in which Phio reports material events. Recent 8-K filings describe clinical milestones for the Phase 1b trial of PH-762 (NCT 06014086), such as completion of enrollment, interim pathology results, and Safety Monitoring Committee findings that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed at reported dose levels. Other 8-Ks detail warrant inducement agreements, gross proceeds from warrant exercises, and the terms of new warrants and placement agent warrants.
Phio’s proxy materials, including its Definitive Proxy Statement on Schedule DEF 14A, outline governance and compensation matters. These filings cover the election of directors, ratification of the independent registered public accounting firm, amendments to the 2020 Long Term Incentive Plan to increase share availability, and advisory votes on executive compensation and the frequency of such votes. They also describe the conduct of the annual meeting and voting results on each proposal.
As Phio advances its INTASYL platform and PH-762 program, investors can use this filings page to monitor financial reporting, capital structure changes, and corporate actions. Stock Titan enhances these documents with AI-powered summaries that highlight key points in complex filings, helping readers quickly identify items such as clinical development updates, financing terms, and board decisions without manually parsing every section.
In addition, the filings page links to disclosures about nonclinical protocol acceptance by the FDA, agreements for cGMP manufacturing of PH-762, and other events that influence the company’s development and financing strategy. For those analyzing PHIO, this centralized view of 8-Ks, proxy statements, and related filings offers a concise way to follow the regulatory record that underpins Phio’s public communications.
Phio Pharmaceuticals Corp. is a clinical-stage biopharma company developing cancer immunotherapies based on its proprietary INTASYL RNA interference platform, designed to make immune cells more effective at killing tumors without complex delivery systems.
Lead candidate PH-762, which targets PD-1, is in a U.S. Phase 1b intratumoral trial for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. Among 20 cutaneous squamous cell carcinoma patients, 65% were pathologic responders, including nine complete responses, with no dose-limiting toxicities reported to date.
Second program PH-894 targets BRD4 and has completed IND-enabling studies, but its IND filing has been deferred while resources are prioritized to PH-762. The company reports significant funding needs, a history of net losses, reliance on third-party manufacturers and CROs, and risks related to maintaining Nasdaq Capital Market listing.
Phio Pharmaceuticals reported 2025 results showing progress in its lead cancer candidate PH-762 and a much stronger balance sheet. The Phase 1b dose-escalation trial of PH-762 completed enrollment with favorable safety, tolerability and pathology data, and the company plans an FDA submission on next-step study design in the second quarter of 2026.
During 2025, equity financings and warrant exercises generated approximately $23.7 million in net proceeds, lifting cash and cash equivalents to about $21.0 million at December 31, 2025, up from $5.4 million a year earlier and extending the cash runway into the first half of 2027. Research and development expenses rose 27% to $4.6 million and general and administrative expenses increased 23% to $4.6 million, reflecting expanded clinical activity and higher professional and compensation costs. Net loss widened to roughly $8.7 million, or $1.45 per share, compared with $7.2 million, or $9.08 per share, in 2024.
Phio Pharmaceuticals Corp. updated its employment agreement with President and Chief Executive Officer Robert J. Bitterman. The amendment increases his protection if he is terminated without cause or leaves for good reason, granting severance equal to twelve months of his base salary in those situations.
The amendment also raises Mr. Bitterman’s annual target bonus opportunity to 50% of his base salary, up from 40% under the prior agreement. The full terms are set out in the Second Amendment filed as an exhibit.
CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership tied to Phio Pharmaceuticals Corp. common stock. They report 1,194,719 shares beneficially owned, representing 9.9% of Phio’s common stock. This amount consists entirely of shares issuable upon exercise of warrants, rather than currently outstanding shares.
The warrants are subject to a 9.99% beneficial ownership limitation, meaning they cannot be exercised if doing so would push the reporting persons and their affiliates above that threshold. Heights Capital Management, Inc., as investment manager to CVI Investments, Inc., may be deemed to share voting and dispositive power, but both parties disclaim beneficial ownership beyond their pecuniary interest. Phio’s quarterly report indicated 10,764,428 shares outstanding as of November 11, 2025.
Phio Pharmaceuticals Corp. received an updated ownership report from Intracoastal Capital LLC and its principals Mitchell P. Kopin and Daniel B. Asher. As of December 31, 2025, they may be deemed to beneficially own 1,142,556 shares of common stock through a warrant held by Intracoastal.
The filing states this represents approximately 9.1% of Phio’s common stock, calculated using 11,447,952 shares outstanding as of December 4, 2025 plus the warrant shares. Additional warrants for 149,298 and 759,298 shares are subject to 4.99% beneficial ownership blocker provisions and are excluded from this percentage.
Without these blocker provisions, the reporting persons may be deemed to beneficially own 2,051,152 shares. They certify the securities were not acquired to change or influence control of Phio Pharmaceuticals, and that the information is true, complete, and correct.
Phio Pharmaceuticals reported encouraging early results from its Phase 1b skin cancer trial of PH-762, its INTASYL gene-silencing compound. The Safety Monitoring Committee completed its planned review and found no dose-limiting toxicities or serious adverse events in 22 patients treated across five escalating dose cohorts.
In cutaneous squamous cell carcinoma, the company reports a 65% overall pathological response rate, with 13 of 20 patients responding, including 9 complete responses with 100% tumor clearance. At the highest dose cohort, 6 of 7 patients showed pathological response and 4 had complete responses.
Phio plans an FDA submission in the second quarter of
Phio Pharmaceuticals director Curtis Lockshin received an equity award in the form of restricted stock units. On February 5, 2026, he was granted 16,600 shares of common stock at a price of $0 per share, reflecting a stock-based compensation grant rather than a purchase.
The filing states these shares represent a restricted stock unit award that will vest on the first anniversary of the grant. Following this grant, Lockshin beneficially owns 35,155 shares of Phio Pharmaceuticals common stock in direct ownership, including shares underlying unvested restricted stock units that have been adjusted for prior reverse stock splits.
Phio Pharmaceuticals director Jonathan E. Freeman received a new equity grant. On 02/05/2026, he was awarded 16,600 shares of common stock at a price of $0, in the form of restricted stock units that will vest on the first anniversary of the grant.
After this award, Freeman beneficially owns 32,655 shares, which include shares underlying unvested restricted stock units. The reported share amounts have been adjusted to account for prior reverse stock splits.
Phio Pharmaceuticals director David H. Deming reported an equity award of 23,800 shares of common stock underlying restricted stock units on February 5, 2026. The filing shows the award was recorded at a price of $0 per share and coded as an acquisition.
These restricted stock units will vest on the first anniversary of the grant, and the total beneficial ownership after this transaction is 37,800 shares held directly, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals reported an equity award to its Chief Financial Officer, Lisa Carson. On 02/05/2026, she received 47,000 shares of common stock for $0, representing a restricted stock unit grant that will vest on the first anniversary of the grant. Following this award, she beneficially owns 94,000 shares of Phio common stock, including shares underlying unvested restricted stock units.